NCT04405843View on ClinicalTrials.gov

Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

476

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
COVID-19
Interventions
DRUG

Ivermectin Oral Product

Ivermectin oral suspension, 6 mg/mL

DRUG

Placebo

Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient

Trial Locations (1)

12345

Centro de Estudios en Infectología Pediátrica, Santiago de Cali

All Listed Sponsors
lead

Centro de Estudios en Infectogía Pediatrica

OTHER

NCT04405843 - Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial) | Biotech Hunter | Biotech Hunter